5:32 PM
 | 
Dec 19, 2012
 |  BC Extra  |  Clinical News

Clinuvel compound improves vitiligo in Phase IIa trial

Clinuvel Pharmaceuticals Ltd. (ASX:CUV; Xetra:UR9) said Scenesse afamelanotide plus narrow-band ultraviolet B (NB-UVB) light met the co-primary endpoints in the Phase IIa CUV102 trial to treat vitiligo. Specifically, four doses of monthly...

Read the full 147 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >